Daniel Morgensztern - Research output - Research Profiles at Washington University School of Medicine

View Scopus Profile

14593

Citations

Research activity per year

117 Article
28 Review article
11 Chapter
9 Editorial
More

9 results

Filter

2024

The expanding role of circulating tumor DNA in resectable non–small cell lung cancer
Morgensztern, D., May 15 2024, In: Cancer. 130, 10, p. 1730-1732 3 p.
Research output: Contribution to journal › Editorial

1 Scopus citations
2021

Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation
Morgensztern, D. & Govindan, R., Dec 2021, In: Journal of Thoracic Oncology. 16, 12, p. 1999-2001 3 p.
Research output: Contribution to journal › Editorial

Open Access

5 Scopus citations
2018

Role of immune checkpoint blockers in patients with EGFR mutation
Ward, J. & Morgensztern, D., Dec 2018, In: Translational Lung Cancer Research. 7, p. S385-S387
Research output: Contribution to journal › Editorial

Open Access

2 Scopus citations
2017

Evolving Treatment Options for Lung Cancer
Morgensztern, D. & Herbst, R. S., Feb 1 2017, In: Hematology/Oncology Clinics of North America. 31, 1, p. xiii-xiv
Research output: Contribution to journal › Editorial

1 Scopus citations
2016

Immune checkpoint inhibition in patients with brain metastases
Johanns, T., Waqar, S. N. & Morgensztern, D., Oct 2016, In: Annals of Translational Medicine. 4, S9.
Research output: Contribution to journal › Editorial

Open Access

10 Scopus citations
Precision medicine in lung cancer: The battle continues
Waqar, S. N. & Morgensztern, D., 2016, In: Journal of Thoracic Disease. 8, 11, p. 2991-2993 3 p.
Research output: Contribution to journal › Editorial

2 Scopus citations
Role for adjuvant chemotherapy in patients with resected small cell lung cancer
Du, L., Waqar, S. N. & Morgensztern, D., 2016, In: Journal of Thoracic Disease. 8, 8, p. 1891-1892 2 p.
Research output: Contribution to journal › Editorial

1 Scopus citations
2015

EGFR mutations in non-small-cell lung cancer: Find, divide, and conquer
Morgensztern, D., Politi, K. & Herbst, R. S., May 1 2015, In: JAMA oncology. 1, 2, p. 146-148 3 p.
Research output: Contribution to journal › Editorial

32 Scopus citations
2012

Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): Impressions from MONET (the motesanib NSCLC efficacy and tolerability study)
Morgensztern, D. & Herbst, R. S., 2012, In: Journal of Clinical Oncology. 30, 23, p. 2805-2808 4 p.
Research output: Contribution to journal › Editorial

Open Access

5 Scopus citations